Document

S-8 1 a2026s-8xeipespp.htm S-8 Document

As filed with the Securities and Exchange Commission on February 25, 2026

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

RECURSION PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)


Delaware						46-4099738
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification Number)

41 S Rio Grande Street

Salt Lake City, UT 84101

(Address of principal executive offices, including zip code)

2021 Equity Incentive Plan
2021 Employee Stock Purchase Plan

(Full title of the plans)

Najat Khan

Chief Executive Officer

Recursion Pharmaceuticals, Inc.

41 S Rio Grande Street

Salt Lake City, UT 84101

(385) 269-0203

(Name, address and telephone number, including area code, of agent for service)

Copies to:

Patrick J. Schultheis

Wilson Sonsini Goodrich & Rosati,

Professional Corporation

701 Fifth Avenue, Suite 5100

Seattle, WA 98104

(206) 883-2500

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☒			Accelerated filer ☐
Non-accelerated filer ☐			Smaller reporting company ☐
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Registration Statement on Form S-8 (this “Registration Statement”) registers additional shares of Class A common stock of Recursion Pharmaceuticals, Inc. (the “Registrant”) under its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan for which (i) a registration statement (No. 333-255315) on Form S-8 was filed with the Securities and Exchange Commission (the “Commission”) on April 16, 2021; (ii) a registration statement (No. 333-264847) on Form S-8 was filed with the Commission on May 10, 2022; (iii) a registration statement (No. 333-271719) on Form S-8 was filed with the Commission on May 8, 2023; (iv) a registration statement (No. 333-279290) on Form S-8 was filed with the Commission on May 10, 2024; and (iv) a registration statement (No. 333-286963) on Form S-8 was filed with the Commission on May 5, 2025 (together, the “Previous Forms S-8”). Pursuant to General Instruction E to Form S-8, the contents of the Previous Forms S-8, including periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement, except that the provisions contained in Part II of such earlier registration statement are modified as set forth in this Registration Statement.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

PART II

INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

(1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Commission on February 25, 2026 (the “Annual Report”);

(2)All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and

(3)The description of the Registrant’s Class A common stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-40323) filed with the Commission on April 12, 2021, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits.

Exhibit

Number

Exhibit Description

Form

Incorporated by
Reference

Filing Date

File No.

Exhibit

4.1

Amended and Restated Certificate of Incorporation of the Registrant

8-K

001-40323

3.1

April 21, 2021

4.2

Amended and Restated Bylaws of the Registrant

8-K

001-40323

3.1

January 31, 2024

4.3

Specimen Class A common stock certificate of the Registrant

S-1/A

333-254576

4.2

April 15, 2021

4.4

2021 Equity Incentive Plan and forms of agreements thereunder

10-K

001-40323

10.3

February 27, 2023

4.5

2021 Employee Stock Purchase Plan and forms of agreements thereunder

S-1/A

333-254576

10.4

April 15, 2021

5.1*

Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

23.1*

Consent of Independent Registered Public Accounting Firm

23.2*

Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

24.1*

Power of Attorney (contained on signature page hereto)

107*

Filing Fee Table

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Salt Lake City, State of Utah, on February 25, 2026.


RECURSION PHARMACEUTICALS, INC.

By:						/s/ Najat Khan
						Najat Khan
						Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Najat Khan and Ben Taylor, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all the said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

Signature

Title

Date

/s/ Najat Khan

Najat Khan

Chief Executive Officer and Director (Principal Executive Officer)

February 25, 2026

/s/ Ben Taylor

Ben Taylor

Chief Financial Officer (Principal Financial and Accounting Officer)

February 25, 2026

Zachary Bogue

Director

February 25, 2026

Blake Borgeson

Director

February 25, 2026

/s/ Namandjé Bumpus

Namandjé Bumpus

Director

February 25, 2026

/s/ Zavain Dar

Zavain Dar

Director

February 25, 2026

/s/ Christopher Gibson

Christopher Gibson

Chair of the Board

February 25, 2026

/s/ Robert Hershberg

Robert Hershberg

Vice Chair and Lead Independent Director of the Board

February 25, 2026

/s/ Dean Li

Dean Li

Director

February 25, 2026

/s/ Franziska Michor

Franziska Michor

Director

February 25, 2026

/s/ Elaine Sun

Elaine Sun

Director

February 25, 2026

SEC Form S-8 filed by Recursion Pharmaceuticals Inc.